AIxCrypto Holdings (AIXC) AI Stock Analysis

• Market Cap: $11.04M
• Dividend Yield: N/A
• Average Volume (3M): 2.38M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: N/A
• EPS Growth: 84.34%
• Country: US
• Employees: 4
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Pharmaceuticals
• EPS (TTM): N/A
• Shares Outstanding: 5,160,382
• 10 Day Avg. Volume: 295,576
• 30 Day Avg. Volume: 2,383,814
• PEG Ratio: <0.01
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.24
• Enterprise Value/Market Cap: -2.23
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 233.00
• Enterprise Value/Ebitda: 3.79
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -35.5
• Revenue Forecast (FY): N/A

• Rating: 31 Underperform
• Price Target: ―

Qualigen Therapeutics' overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.

AIxCrypto Holdings Business Overview & Revenue Model

Company Description

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.

How the Company Makes Money

Qualigen Therapeutics generates revenue through multiple streams, primarily focusing on the development and commercialization of its therapeutic products. The company earns money by advancing its drug candidates through clinical trials and securing partnerships or licensing agreements with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of clinical and regulatory goals, and royalties on product sales. Additionally, Qualigen may derive revenue from its diagnostic technologies, which are used in clinical settings and research institutions. The company's financial performance is significantly influenced by its ability to successfully bring its drug candidates to market and establish strategic partnerships within the pharmaceutical industry.

AIxCrypto Holdings Financial Statement Overview

Summary

Qualigen Therapeutics faces significant financial challenges. The income statement reveals persistent revenue declines and substantial losses, while the balance sheet highlights financial instability with negative equity. Cash flow analysis indicates ongoing operational cash burn and reliance on financing. The company needs strategic financial management and operational improvements to stabilize its financial health.

Income Statement

Qualigen Therapeutics has experienced declining revenue recently, with the latest TTM period showing zero revenue. The company consistently reports significant net losses, evidenced by a negative net profit margin across recent periods. Gross profit margins are also negative, indicating cost management challenges. Historical revenue growth has been inconsistent, with recent declines. EBIT and EBITDA margins remain negative, highlighting operational inefficiencies and profitability issues.

Balance Sheet

The balance sheet shows significant financial distress, with negative stockholders' equity in the latest TTM period, indicating liabilities exceed assets. The company's debt-to-equity ratio is not meaningful due to negative equity, but high liabilities relative to assets suggest financial instability. Return on equity is negative, reflecting ongoing losses, and the equity ratio is concerning due to negative equity.

Cash Flow

Cash flow analysis shows negative operating cash flows, highlighting operational challenges. Free cash flow has been negative, indicating cash burn that may threaten sustainability without external financing. The company has relied on financing activities, as shown by cash inflows from financing, to support operations. Overall, cash flow metrics reflect a need for improved cash management and operational performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	5.65M	4.31M
Gross Profit	-105.58K	0.00	0.00	680.80K	1.32M	-2.88M
EBITDA	-6.48M	-5.24M	-10.95M	-13.84M	-22.32M	-11.16M
Net Income	-7.23M	-6.26M	-13.42M	-18.64M	-17.90M	-20.42M
Balance Sheet
Total Assets	43.47M	4.69M	2.03M	19.08M	22.84M	29.13M
Cash, Cash Equivalents and Short-Term Investments	38.78M	1.17M	401.80K	3.17M	17.54M	23.98M
Total Debt	3.24M	0.00	1.30M	1.76M	1.68M	630.30K
Total Liabilities	4.92M	2.01M	4.14M	10.32M	6.27M	10.83M
Stockholders Equity	38.55M	2.68M	-2.10M	7.24M	16.56M	18.29M
Cash Flow
Free Cash Flow	-7.10M	-6.33M	-10.30M	-13.57M	-14.87M	-9.97M
Operating Cash Flow	-7.10M	-6.33M	-10.30M	-13.25M	-14.73M	-9.76M
Investing Cash Flow	-2.82M	-1.91M	4.22M	-183.76K	-141.36K	-160.56K
Financing Cash Flow	48.30M	9.01M	-550.00K	2.91M	8.43M	33.76M

AIxCrypto Holdings Technical Analysis

• Last Price: 2.65

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIXC, the sentiment is undefined. The current price of 2.65 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for AIXC.

AIxCrypto Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%

AIxCrypto Holdings Corporate Events

AIxCrypto Holdings Regains Nasdaq Compliance After Issue

AIxCrypto Holdings recently faced a compliance issue with Nasdaq Listing Rule 5635(b) due to a private placement transaction that closed on September 29, 2025, which led to significant changes in the company’s management and board of directors. Despite initially failing to obtain shareholder approval, the company has since regained compliance with the rule and remains listed on the Nasdaq Capital Market, although it will be monitored for a year to ensure continued compliance with Nasdaq’s equity rule.

AIxCrypto Holdings Rebrands, Unveils New Strategy

On November 20, 2025, AIxCrypto Holdings, Inc. announced its rebranding from Qualigen and began trading under the new ticker AIXC. The company unveiled its ‘Three Driving Forces’ strategy aimed at becoming the leading gateway to the AI Web3 world, focusing on AI-driven trading infrastructure, crypto asset management, and decentralized technology protocols. The rebranding marks the completion of the FFAI + AIXC ‘dual flywheel, dual bridge, dual listing’ system, which is expected to enhance integration between Web2 and Web3, providing transformative value and growth opportunities. The company plans to achieve its goals through product innovation, strategic investments, and partnerships, aiming to create a robust digital ecosystem.